NAS:DNLI (USA) Also trade in: Germany

Denali Therapeutics Inc

$ 19.75 0.2 (1.02%)
Volume: 410,797 Avg Vol (1m): 400,625
Market Cap $: 1.89 Bil Enterprise Value $: 1.40 Bil
P/E (TTM): 0.00 P/B: 3.58
Earnings Power Value 0
Net Current Asset Value 3.58
Tangible Book 5.44
Projected FCF 0
Median P/S Value 675.73
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

GuruFocus Articles Total 16
  • 1

  • DNL310 on track to enter Phase 1/2 clinical study in Hunter Syndrome patients in 2020
  • DNL310 utilizes Denali’s proprietary blood-brain barrier crossing enzyme transport vehicle (“ETV”) technology
  • Two additional ETV-enabled enzyme replacement programs were advanced to pre-clinical testing             

SOUTH SAN FRANCISCO, Calif., June 11, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that the FDA granted Orphan Drug Designation (“ODD”) and Rare Pediatric Disease Designation for Denali’s DNL310

0 Views    Marketwired    2019-06-11 16:01

SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2019.

First Quarter 2019 Financial Results

For the three months ended March 31, 2019, Denali reported a net loss of $39.0 million compared with a net loss of $23.7 million for the three months ended March 31, 2018.

Collaboration revenue was $4.2 million for the three months ended March 31,

0 Views    Marketwired    2019-05-09 00:00

SOUTH SAN FRANCISCO, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided business highlights.

“We have made significant progress toward our long-term goal of defeating neurodegenerative diseases. We successfully completed Phase 1 healthy volunteer clinical trials for our LRRK2 inhibitor and RIPK1 inhibitor programs, initiated clinical studies in patients with Parkinson’s disease, ALS and

0 Views    Marketwired    2019-03-12 16:02
The height of folly

The height of folly.

That’s what I call it when people pay 100 times a company’s pre-share revenue to buy a stock. You see this behavior mostly with young biotechnology stocks and fledgling technology stocks.

Investors mentally build what economics professor Burton Malkiel called “castles in the sky” when they drool over the potential in these stocks.

Of course, it’s possible to luck out if you catch the “next NVidia” but the odds are strongly against you.

Over the years, beginning in 2000, I’ve written 14 columns warning against investing in these sky-high stocks. The stocks I warned against have

764 Views    John Dorfman    2019-02-19 20:42

NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Walgreens Boots Alliance, Inc. (WBA), Live Nation Entertainment, Inc. (:LYV), Denali Therapeutics Inc. (DNLI), Haynes International, Inc. (HAYN), NV5 Global, Inc. (NVEE), and Johnson Outdoors Inc. (JOUT), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers

0 Views    Marketwired    2019-02-19 13:03

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of DNL747 in patients with Alzheimer’s disease, in collaboration with its partner Sanofi.

“We are excited to advance DNL747 in a second neurodegeneration indication based on Phase 1 healthy volunteer data regarding DNL747’s safety profile, CNS penetration, and target engagement, at the studied doses.” said

0 Views    Marketwired    2019-02-15 17:03

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of DNL747 in patients with ALS, in collaboration with its partner Sanofi.

“Based on Phase 1 data in healthy volunteer subjects demonstrating DNL747’s excellent CNS penetration, safety profile, and ability to inhibit the RIPK1 pathway, we are excited to evaluate DNL747 in ALS patients,” said

0 Views    Marketwired    2019-01-08 17:03

  • Phase 1b study includes Parkinson’s disease patients with and without a genetic LRRK2 mutation

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of DNL201 in patients with Parkinson’s disease.

“Based on the positive outcome of our Phase 1 study in 122 healthy volunteer subjects, we are excited to evaluate DNL201 in Parkinson’s disease

0 Views    Marketwired    2018-12-10 17:04

SOUTH SAN FRANCISCO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2018, provided business highlights and announced the appointment of Jennifer Cook to the Board of Directors.

“The recent clinical progress with our LRRK2 inhibitor and RIPK1 inhibitor programs are important milestones towards our goal of developing medicines for patients suffering from neurodegenerative diseases,” said Ryan Watts, Ph.D., CEO. “Furthermore,

0 Views    Marketwired    2018-11-09 01:02

  • Candidate RIPK1 inhibitor molecules have the potential to treat Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and systemic inflammatory diseases
  • Denali to receive $125 million upfront payment and future milestone payments that could exceed $1 billion
  • Denali and Sanofi plan to jointly develop and commercialize programs for neurological indications, and Sanofi will develop and commercialize programs for systemic inflammatory indications

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for

0 Views    Marketwired    2018-11-01 08:00

CENTOGENE to conduct a targeted global identification and recruitment campaign to support Denali´s LRRK2 inhibitor program

ROSTOCK, Germany and SOUTH SAN FRANCISCO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- CENTOGENE and Denali Therapeutics ( DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation carrier Parkinson’s disease (“PD”) patients.

CENTOGENE will conduct a targeted global recruitment campaign focused on the early identification and characterization of LRRK2 PD patients and sequence the LRRK2 gene in these patients. Under the

0 Views    Marketwired    2018-10-03 16:09

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2018.

Second Quarter 2018 Financial Results

For the three months ended June 30, 2018, Denali reported a net loss of $54.7 million compared with a net loss of $22.1 million for the three months ended June 30, 2017.

Collaboration revenue was $1.6 million for the three months ended June 30, 2018,

0 Views    Marketwired    2018-08-10 00:02

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that Dr. Dana Andersen has joined the company as Chief Technical and Manufacturing Officer.

Dr. Andersen joins Denali from Genentech, where he served in various roles for nearly 23 years, working most recently as Vice President and Global Head of Technical Development Project & Portfolio Management. Prior to this role, he was Vice President of Pharmaceutical Development

0 Views    Marketwired    2018-08-08 00:04

  • Healthy volunteer study of DNL201 meets all objectives in phase 1 clinical study, including CSF exposure levels and LRRK2 inhibition, as well as pathway engagement, at doses that were safe and well tolerated
  • DNL201 will advance to Phase 1b in Parkinson’s disease patients with and without a genetic LRRK2 mutation

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced positive results from its Phase 1 clinical study

0 Views    Marketwired    2018-08-02 00:02

SOUTH SAN FRANCISCO, May 30, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it has exercised its option to acquire all outstanding shares in F-star Gamma pursuant to the Option Agreement dated August 24, 2016 and expanded its collaboration with F-star on Denali’s biologics Transport Vehicle (“TV”) blood-brain barrier (“BBB”) platform technology.

Denali entered into a License and Collaboration Agreement with F-star in August 2016 to support the development of and

0 Views    Marketwired    2018-05-31 00:00

SOUTH SAN FRANCISCO, Calif., May 11, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2018.

First Quarter 2018 Financial Results

For the three months ended March 31, 2018, Denali reported a net loss of $23.7 million, compared with a net loss for the three months ended March 31, 2017 of $21.3 million.

Collaboration Revenue was $0.6 million for the three months ended March 31, 2018,

0 Views    Marketwired    2018-05-11 16:02

Headlines Total 49
  • 1

2019-06-12 $19.03 (0.63%)
12:10pm
9:30am
2019-06-11 $18.91 (1.5%)
11:01am
2019-05-08 $23.53 (0.13%)
7:05pm
7:00pm
2019-05-03 $24.63 (1.65%)
9:30am
2019-04-10 $28.14 (0.9%)
10:03am
2019-03-12 $22.2 (1.79%)
11:02am
9:35am
2019-02-19 $21.47 (2.38%)
2:42pm
2019-02-15 $20.97 (3.5%)
11:03am
2019-01-25 $21.85 (1.91%)
7:00am
2019-01-08 $20.25 (2.07%)
11:03am
2018-12-10 $20.23 (3.37%)
11:04am
2018-11-08 $17.35 (-0.12%)
7:02pm
2018-11-05 $16.79 (-1.06%)
8:56am
2018-11-01 $16.33 (12.85%)
3:00am
2018-10-03 $21.2 (-2.53%)
11:09am
2018-09-14 $19.5 (7.44%)
2:38pm
2018-08-29 $18.02 (2.1%)
7:13am
2018-08-09 $15.3 (0.99%)
7:02pm
2018-08-07 $15.63 (4.2%)
7:04pm
10:13am
2018-08-06 $15 (8.23%)
10:35am
2018-08-03 $13.86 (-1%)
12:56am
12:17am
2018-08-01 $12.73 (1.11%)
7:02pm
2018-07-17 $14 (-0.36%)
9:11pm
2018-06-13 $18.92 (0.91%)
2:22pm
2018-05-30 $20.73 (-0.29%)
7:00pm
2018-05-29 $20.79 (4.32%)
6:17am
2018-05-11 $19.44 (-5.17%)
11:02am
2018-05-09 $19.47 (4.01%)
5:37am
2018-04-05 $18.89 (-3.62%)
7:53am
2018-03-20 $22.06 (0.46%)
8:00am
2018-03-02 $22.59 (4.73%)
3:00pm
2018-02-28 $22.89 (6.42%)
5:05pm
2018-02-08 $20.89 (3.06%)
3:26pm
2018-01-16 $17.1 (-0.35%)
8:54am
2018-01-05 $16.8 (4.48%)
11:17am
2017-12-16
6:27pm
2017-12-11 $20.99 (-2.14%)
7:07am
2017-12-09
7:41am
2017-12-08 $21.45 (%)
11:21am
8:37am
2017-12-02
5:23am
1969-12-31
7:00pm
7:00pm
Here's When You Can Buy Twitter's Stock - realmoney.thestreet.com
7:00pm
This Market Badly Needs a Rest - realmoney.thestreet.com
Total 49
  • 1